Literature DB >> 32420194

Local staging of prostate cancer with imaging: can hybrid imaging be the solution?

Baris Turkbey1.   

Abstract

Entities:  

Year:  2020        PMID: 32420194      PMCID: PMC7214973          DOI: 10.21037/tau.2020.03.12

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
Accurate local staging is crucial in clinical management of prostate cancer (1). Currently, multiparametric magnetic resonance (mpMRI) is the most established imaging method for local staging and although this imaging modality offers a high-resolution capability, it is still limited in staging of prostate cancer, mainly for microscopic capsular involvement. Initial studies had focused on a binary approach for prediction of extraprostatic extension (EPE), whereas later studies aimed to utilize some subjective (e.g., capsular bulge, irregularity) (2) and few objective measures (e.g., lesion-capsule contact length) (3). Most recently, few studies have reported development of more objective scoring systems for EPE prediction in prostate cancer patients (4). Despite all efforts, capability of mpMRI in local staging is still limited and not convincing enough to be used routinely. Targeted imaging with positron emission tomography (PET) tracers such as prostate specific membrane antigen (PSMA) has a documented role in detecting clinically significant prostate cancers and bone and nodal metastases (5); however, its utility for local staging is not widely studied. In this single center retrospective study, Muehlematter et al. aim to compare diagnostic accuracy and inter-reader agreement of mpMRI and PSMA PET/MRI in 40 patients who were diagnosed with intermediate and high-risk prostate cancer at the preoperative phase (6). The authors used a Likert system for independent evaluation of EPE and seminal vesicle invasion (SVI) on mpMRI and PSMA PET/MRI. Their results indicated that mpMRI and PSMA PET/MRI have similar sensitivities for the detection of EPE and SVI. Only at the region level, specificity of mpMRI was significantly higher than PSMA PET/MRI for EPE and SVI detection. The resultant accuracies were similar for both imaging techniques. Moreover, inter-reader agreement was moderate for EPE but was low for SVI and similar for both mpMRI and PSMA PET/MRI (). The authors conducted an extensive analysis in this retrospective study, however their study population was relatively small, and the cohort included a relatively high proportion of high risk prostate cancer patients, which limits the generalizability of their findings to the larger patient populations in which practicing physicians need to utilize imaging.
Figure 1

Visual abstract of “Diagnostic accuracy of multiparametric MRI versus ” (6).

Visual abstract of “Diagnostic accuracy of multiparametric MRI versus ” (6). One important aspect of this study could have been whether MRI or PSMA PET component contributed EPE and SVI detection in the PET/MRI arm. However, this was not formally studied in this study. Theoretically, PSMA can be helpful to detect subtle SVI where background signal does not overlap with tumor related uptake, whereas its contribution for EPE detection, which is heavily dependent on morphologic features and resultant high in-plane resolution may be limited due to the low spatial resolution nature of PET imaging. In future studies, it may be useful to compare MRI and PSMA PET alone for local staging. In conclusion, local staging is an important aspect of prostate cancer and reported utility of imaging is still limited for this indication. The study by Muehlematter et al. is quite encouraging to explore use of targeted molecular imaging in conjunction with anatomic MRI. As mentioned by the authors, this use of PSMA PET/MRI comes with a cost of lower specificity for local staging of prostate cancer. It will be quite interesting to observe prospective use of hybrid imaging in larger patient populations with more diverse disease risk categories. The article’s supplementary files as
  6 in total

1.  Length of capsular contact for diagnosing extraprostatic extension on prostate MRI: Assessment at an optimal threshold.

Authors:  Andrew B Rosenkrantz; Alampady K Shanbhogue; Annie Wang; Max Xiangtian Kong; James S Babb; Samir S Taneja
Journal:  J Magn Reson Imaging       Date:  2015-09-23       Impact factor: 4.813

2.  Prostate cancer: local staging at 3-T endorectal MR imaging--early experience.

Authors:  Jurgen J Fütterer; Stijn W T P J Heijmink; Tom W J Scheenen; Gerrit J Jager; Christina A Hulsbergen-Van de Kaa; J Alfred Witjes; Jelle O Barentsz
Journal:  Radiology       Date:  2005-11-22       Impact factor: 11.105

Review 3.  Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.

Authors:  Thomas A Hope; Ali Afshar-Oromieh; Matthias Eiber; Louise Emmett; Wolfgang P Fendler; Courtney Lawhn-Heath; Steven P Rowe
Journal:  AJR Am J Roentgenol       Date:  2018-06-27       Impact factor: 3.959

4.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients.

Authors:  Gerald W Hull; Farhang Rabbani; Farhat Abbas; Thomas M Wheeler; Michael W Kattan; Peter T Scardino
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

5.  Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.

Authors:  Urs J Muehlematter; Irene A Burger; Anton S Becker; Khoschy Schawkat; Andreas M Hötker; Cäcilia S Reiner; Julian Müller; Niels J Rupp; Jan H Rüschoff; Daniel Eberli; Olivio F Donati
Journal:  Radiology       Date:  2019-09-10       Impact factor: 11.105

6.  A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.

Authors:  Sherif Mehralivand; Joanna H Shih; Stephanie Harmon; Clayton Smith; Jonathan Bloom; Marcin Czarniecki; Samuel Gold; Graham Hale; Kareem Rayn; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2019-01-22       Impact factor: 11.105

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.